Advanced searches left 3/3

Multiple Sclerosis - Crossref

Summarized by Plex Scholar
Last Updated: 13 August 2022

* If you want to update the article please login/register

Longitudinal clinical study of patients with white matter iron rims lesions in multiple sclerosis

Iron rims surrounding white matter lesions are able to predict a more prevalent disease course. So far, only small longitudinal cohorts of patients with and without IRL have been reported so far. Objective: To determine if the presence and number of IRL in patients with CIS and MS are related to increased long-term clinical disability. Methods Ninety-One CIS/MS patients were recruited between 2008 and 2013 and scanned with 7T MRI for ninety-one CIS/MS patients. In 42 patients, 132 IRLs were found. Patients with IRL at baseline had higher EDSS and ARMSS. Presence of IRL was also a predictor of long-term disability, particularly in those patients with a U22654 IRL. The effect of IRL on disability was greater than the baseline WML figures, another common prognostic biomarker. Conclusions The presence and number of perilesional IR at a baseline scan suggest prognostic value for long-term medical disability in MS.

Source link: https://doi.org/10.1136/jnnp-2022-abn2.27


148 Treating newly diagnosed relapsing-remitting multiple sclerosis (RRMS): a 2021 clinician survey in the United Kingdom

Background: Background As new treatment options are available for RRMS, it is crucial to know clinical treatment decision-making. Methods We used a structured questionnaire to poll UK healthcare professionals about their clinical treatment strategies for RRMS. Output: The findings of 38 HCPs surveyed, 53% were multiple sclerosis consultants, 34% MS specialist nurses, and 11% neurologists with an MS interest were among the 11% neurologists with an MS interest. According to 66% of respondents, the treatment strategy they want to take was determined by the treatment approach they wanted to take. The estimated percentage of patients treated with high efficacy early or escalation strategies were 42. 1% and 58. 3%, respectively; 66% of respondents agreed that these figures represented the patient population treated with high efficacy early or escalation techniques.

Source link: https://doi.org/10.1136/jnnp-2022-abn2.192


145 Long-term safety of ofatumumab in patients with relapsing multiple sclerosis

Patients with relapsing multiple sclerosis syndromes are susceptible to long-term exposure and tolerability of ofatumumab therapy in patients with relapsing multiple sclerosis. Methods Patients Completing the core ASCLEPIOS I/II, APOLITOS, and APLIOS trials may be enrolled in ALITHIOS, an ongoing, open-label extension trial. Results In studies published by ALITHIOS, a manufacturer of atumumab therapy for up to 3. 5 years, reported 83. 9% of patients had u22651 AEs and 9. 7% had u22651 serious AEs with a low incidence of serious infections and malignancies, with a low risk of serious infections and malignancies. Conclusions Safety data from up to 3. 5 years indicates that the use of atumumab therapy has been generally well-tol-erated with no new safety risks identified.

Source link: https://doi.org/10.1136/jnnp-2022-abn2.189


144 Long-term efficacy of ofatumumab in patients with relapsing multiple sclerosis

Objective The aim of this study was to determine the long-term effects of ofatumumab therapy in patients with relapsing multiple sclerosis. Patients will be analyzed in two groups: those randomly assigned to ofatumab in the center and those randomised to teriflunomide in the center, with the possibility of a switch to ofatumumab in the extension. Patients treated with teriflunomide in ALITHIOS have been treated in total, 690/946 patients treated with ofatumab and 677/936 patients. Conclusions These reports will provide insight into the continued efficacy of continuous oatumumab therapy in RMS patients for up to four years and on ofatumumab efficacy in patients newly switched from teriflunomide.

Source link: https://doi.org/10.1136/jnnp-2022-abn2.188


120 UK multiple sclerosis registries project: disease modifying treatment durability

We investigated disease-modifying therapy adherence in a nationwide sample of people with Multiple Sclerosis (MS) here. Results Two-year durability was the longest for immune reconstitution therapies cladribine, ocrelizumab, and alemtuzumab, according to two-year results. Fingolimod and dimethyl fumarate were found in Oral medications, and intravenous natalizumab demonstrated similar tenacity. Variable date of DMT licency, change in DMT algorithms over time, and increasing DMT options are among the potential confounding factors. These findings may help with DMT clinical decision-making and improve outcomes for pwMS.

Source link: https://doi.org/10.1136/jnnp-2022-abn2.164


129 Multiple sclerosis relapse patterns in a population-based cohort

Although DMT prescribing continues to rise, it is uncertain what effect this has on relapse frequency and phenotype as DMT prescribing continues to rise. Prospectively gathered relapse data from the South Wales MS registry from 2000- 2020 was examined from 2000-2020. Over time epochs, the relapse rate and phenotype attributed to DMT use were determined. DMT use soared from 6% to 31%, according to a cross-sectional review of data from years 2005 to 2020, and ARR was strongly associated with DMT use. Conclusion - In this population-based MS cohort, increasing usage of DMTs has been linked to lower ARR reduction for the last 20 years.

Source link: https://doi.org/10.1136/jnnp-2022-abn2.173


Effectiveness of COVID-19 vaccines in multiple sclerosis patients receiving disease-modifying therapies in England

We want to know how MS DMTs influence the clinical effectiveness of COVID-19 vaccines by a study. DMT patients in England from December-2020 to January-2022 were analyzed by We collected the records of all MS patients receiving DMTs from December-2020 to January-2022. At least two COVID-19 vaccines were administered to at least 38,039 MS patients on DMTs. Patients on ocrelizumab have elevated incidences of COVID-19-related inflammation and hospitalization compared to other DMTs using new vaccination strategies. Patients on fingolimod also have higher incidences of post-virus disease, but their hospitalization rate is similar to other DMTs.

Source link: https://doi.org/10.1136/jnnp-2022-abn2.21


118 Acute disseminated encephalomyelitis associated with SARS-CoV-2 vaccine in multiple sclerosis: a case report

In a patient previously diagnosed with multiple sclerosis, we report a case of acute disseminated encephalomyelitis three weeks after the AstraZeneca SARS-CoV-2 vaccine in a patient previously diagnosed with multiple sclerosis. Conclusions: ADEM has now been associated with a variety of SARS-CoV-2 vaccines, but the risk of SARS-CoV-2 infection remains extremely low in comparison to SARS-CoV-2 infections. This is the first reported case of ADEM in a patient with multiple sclerosis following SARS-CoV-2 vaccination. SARS-CoV-2 infections have an elevated risk of multiple sclerosis exacerbations, according to literature.

Source link: https://doi.org/10.1136/jnnp-2022-abn2.162

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions